Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Suramin, at non-cytotoxic doses, reverses chemoresistance and enhances the activity of mitomycin C (MMC) in mice bearing human bladder xenograft tumors. The present study evaluated the pharmacokinetics of the intravesical suramin and MMC, alone or in combination, in dogs. Animals received either high dose suramin (20 mg/ml), low dose suramin (6 mg/ml), MMC (2 mg/ml), or combination of low dose suramin and MMC, instilled for 2 h. The dosing volume was 20 ml. All groups showed dilution of drug levels over time due to continued urine production. For single agent suramin, the results showed (a) 5% to 10% penetration into bladder tissues, (b) minimal and clinically insignificant systemic absorption (i.e., undetectable at low dose or a peak concentration that was 6,000× lower than urine concentrations), and (c) disproportionally higher drug penetration and concentrations in bladder tissues at the higher dose. Results for single agent MMC are consistent with our earlier observations. The co-administration of MMC did not alter the plasma, urine, or tissue pharmacokinetics of suramin. Adding suramin did not alter plasma or tissue pharmacokinetics of MMC, but lowered the MMC concentrations in urine by about 20%. This may be in part due to accelerated MMC degradation by co-incubation of suramin or due to variations in urine production rate (because animals were allowed for water during treatment). Suramin readily penetrates the urothelium and into deeper bladder tissues, indicating its potential utility in intravesical therapy.
Hu
Leijun
L
The Ohio State University, Columbus, 43210, USA.
Wientjes
M Guillaume
MG
Li
Jing
J
Au
Jessie L-S
JL
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D004285:Dogs; D005260:Female; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D013498:Suramin / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000652:urine; D001743:Urinary Bladder / Q000378:metabolism*
D000970:Antineoplastic Agents; D016685:Mitomycin; D013498:Suramin